These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47 related articles for article (PubMed ID: 2628304)
21. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729 [TBL] [Abstract][Full Text] [Related]
22. A dose-response study in situational insomnia with zopiclone, a new tranquilizer. Giercksky KE; Wickstrom E Clin Ther; 1980; 3(1):21-7. PubMed ID: 6996815 [TBL] [Abstract][Full Text] [Related]
23. Tolerance and pharmacokinetics of oral fendiline. Weyhenmeyer R; Fenzl E; Apecechea M; Rehm KD; Dyde CJ; Johnson KJ; Friedel R Arzneimittelforschung; 1987 Jan; 37(1):58-62. PubMed ID: 3566858 [TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562 [TBL] [Abstract][Full Text] [Related]
25. Multiple-dose, placebo-controlled, phase I study of oral dolasetron. Hunt TL; Cramer M; Christy-Bittel J; Shah AK; Meyerson LJ; Benedict CR; Hahne WF Pharmacotherapy; 1996; 16(2):253-60. PubMed ID: 8820469 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837 [TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552 [TBL] [Abstract][Full Text] [Related]
28. Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Amsterdam JD; Dunner DL; Fabre LF; Kiev A; Rush AJ; Goodman LI Pharmacopsychiatry; 1989 Jul; 22(4):137-43. PubMed ID: 2668978 [TBL] [Abstract][Full Text] [Related]
29. A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. Søgaard U; Michalow J; Butler B; Lund Laursen A; Ingersen SH; Skrumsager BK; Rafaelsen OJ Int Clin Psychopharmacol; 1990 Oct; 5(4):237-51. PubMed ID: 2150527 [TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacology of a new antidepressant, Y-8894 in healthy young and elderly volunteers. Ogura C; Kishimoto A; Kunimoto N; Omura F; Matsubayashi M; Tsutsui T; Shimizu M Br J Clin Pharmacol; 1987 May; 23(5):537-43. PubMed ID: 3593624 [TBL] [Abstract][Full Text] [Related]
31. Multiple-dose phase I trials--normal volunteers or patients? One viewpoint. Weissman L J Clin Pharmacol; 1981 Oct; 21(10):385-7. PubMed ID: 7309900 [TBL] [Abstract][Full Text] [Related]
33. Multicentric efficacy study of centpropazine and imipramine in depressed patients. Srivastava JS; Asthana OP; Singh H; Agarwal AK; Shah LP; Sharma KC; Gopinath PS; Srimal RC Indian J Psychiatry; 1999 Jul; 41(3):249-53. PubMed ID: 21455398 [TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacological studies on centpropazine--a new antidepressant compound. Gupta PP; Asthana OP; Tangri AN; Dhawan BN Indian J Med Res; 1989 Oct; 90():360-2. PubMed ID: 2628304 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Geisser P; Banké-Bochita J Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136 [TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. Vaughan D; Speed J; Medve R; Andrews JS Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420 [TBL] [Abstract][Full Text] [Related]